Therapeutic target database update 2018: Enriched resource for facilitating bench-to-clinic research of targeted therapeutics

Nucleic Acids Research

Volumn 46, Issue D1, 2018, Pages D1121-D1127

  Li, Ying Hong ^a,c   Yu, Chun Yan ^a,c   Li, Xiao Xu ^a,c   Zhang, Peng ^a   Tang, Jing ^c   Yang, Qingxia ^c   Fu, Tingting ^c   Zhang, Xiaoyu ^c   Cui, Xuejiao ^c   Tu, Gao ^c   Zhang, Yang ^c   Li, Shuang ^c   Yang, Fengyuan ^c   Sun, Qiu ^c   Qin, Chu ^a   Zeng, Xian ^a   Chen, Zhe ^d   Chen, Yu Zong ^a   Zhu, Feng ^a,b,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b ZHEJIANG UNIVERSITY   (China)

^c CHONGQING UNIVERSITY   (China)

^d ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID SEQUENCE; ARTICLE; BENCHMARKING; CLINICAL RESEARCH; DRUG RESISTANCE; DRUG TARGETING; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC DATABASE; GENETIC SIMILARITY; HUMAN; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; REGULATOR GENE; SEQUENCE ANALYSIS; DRUG COMBINATION; DRUG THERAPY; FACTUAL DATABASE; GENETICS; INTERNET; MOLECULARLY TARGETED THERAPY; MUTATION;

DATABASES, FACTUAL; DRUG COMBINATIONS; DRUG RESISTANCE; DRUG THERAPY; GENE EXPRESSION; HUMANS; INTERNET; MOLECULAR TARGETED THERAPY; MUTATION;

EID: 85040867496     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Munos, B. (2009) Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov., 8, 959-968.
2. Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I. et al. (2017) A comprehensive map of molecular drug targets. Nat. Rev. Drug Discov., 16, 19-34.
3. Imming, P., Sinning, C. and Meyer, A. (2006) Drugs, their targets and the nature and number of drug targets. Nat. Rev. Drug Discov., 5, 821-834.
4. Zhang, X. D., Song, J., Bork, P. and Zhao, X. M. (2016) The exploration of network motifs as potential drug targets from post-translational regulatory networks. Sci. Rep., 6, 20558.
5. Lee, A., Lee, K. and Kim, D. (2016) Using reverse docking for target identification and its applications for drug discovery. Expert Opin. Drug Discov., 11, 707-715.
6. Wang, P., Zhang, X., Fu, T., Li, S., Li, B., Xue, W., Yao, X., Chen, Y. and Zhu, F. (2017) Differentiating physicochemical properties between addictive and nonaddictive ADHD drugs revealed by molecular dynamics simulation studies. ACS Chem. Neurosci., 8, 1416-1428.
7. Zheng, C. J., Han, L. Y., Yap, C. W., Ji, Z. L., Cao, Z. W. and Chen, Y. Z. (2006) Therapeutic targets: progress of their exploration and investigation of their characteristics. Pharmacol. Rev., 58, 259-279.
8. Rask-Andersen, M., Almen, M. S. and Schioth, H. B. (2011) Trends in the exploitation of novel drug targets. Nat. Rev. Drug Discov., 10, 579-590.
9. Chen, B. and Butte, A. J. (2016) Leveraging big data to transform target selection and drug discovery. Clin. Pharmacol. Ther., 99, 285-297.
10. Wang, P., Fu, T., Zhang, X., Yang, F., Zheng, G., Xue, W., Chen, Y., Yao, X. and Zhu, F. (2017) Differentiating physicochemical properties between NDRIs and sNRIs clinically important for the treatment of ADHD. Biochim. Biophys. Acta, 1861, 2766-2777.
11. Yang, H., Qin, C., Li, Y. H., Tao, L., Zhou, J., Yu, C. Y., Xu, F., Chen, Z., Zhu, F. and Chen, Y. Z. (2016) Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information. Nucleic Acids Res., 44, D1069-D1074.
12. Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A. C., Liu, Y., Maciejewski, A., Arndt, D., Wilson, M., Neveu, V. et al. (2014) DrugBank 4. 0: shedding new light on drug metabolism. Nucleic Acids Res., 42, D1091-D1097.
13. Gaulton, A., Hersey, A., Nowotka, M., Bento, A. P., Chambers, J., Mendez, D., Mutowo, P., Atkinson, F., Bellis, L. J., Cibrian-Uhalte, E. et al. (2017) The ChEMBL database in 2017. Nucleic Acids Res., 45, D945-D954.
14. Southan, C., Sharman, J. L., Benson, H. E., Faccenda, E., Pawson, A. J., Alexander, S. P., Buneman, O. P., Davenport, A. P., McGrath, J. C., Peters, J. A. et al. (2016) The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res., 44, D1054-D1068.
15. Ursu, O., Holmes, J., Knockel, J., Bologa, C. G., Yang, J. J., Mathias, S. L., Nelson, S. J. and Oprea, T. I. (2017) DrugCentral: online drug compendium. Nucleic Acids Res., 45, D932-D939.
16. Ito, J., Ikeda, K., Yamada, K., Mizuguchi, K. and Tomii, K. (2015) PoSSuM v. 2. 0: data update and a new function for investigating ligand analogs and target proteins of small-molecule drugs. Nucleic Acids Res., 43, D392-D398.
17. Wang, C., Hu, G., Wang, K., Brylinski, M., Xie, L. and Kurgan, L. (2016) PDID: database of molecular-level putative protein-drug interactions in the structural human proteome. Bioinformatics, 32, 579-586.
18. Kim, P., Cheng, F., Zhao, J. and Zhao, Z. (2016) ccmGDB: a database for cancer cell metabolism genes. Nucleic Acids Res., 44, D959-D968.
19. Gohlke, B. O., Nickel, J., Otto, R., Dunkel, M. and Preissner, R. (2016) CancerResource-updated database of cancer-relevant proteins, mutations and interacting drugs. Nucleic Acids Res., 44, D932-D937.
20. Zhu, F., Qin, C., Tao, L., Liu, X., Shi, Z., Ma, X., Jia, J., Tan, Y., Cui, C., Lin, J. et al. (2011) Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting. Proc. Natl. Acad. Sci. U. S. A., 108, 12943-12948.
21. Hughes, D. and Andersson, D. I. (2015) Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms. Nat. Rev. Genet., 16, 459-471.
22. Schmitt, M. W., Loeb, L. A. and Salk, J. J. (2016) The influence of subclonal resistance mutations on targeted cancer therapy. Nat Rev. Clin Oncol., 13, 335-347.
23. Kumar, V., Sanseau, P., Simola, D. F., Hurle, M. R. and Agarwal, P. (2016) Systematic analysis of drug targets confirms expression in disease-relevant tissues. Sci. Rep., 6, 36205.
24. Zhu, F., Han, B., Kumar, P., Liu, X., Ma, X., Wei, X., Huang, L., Guo, Y., Han, L., Zheng, C. et al. (2010) Update of TTD: Therapeutic Target Database. Nucleic Acids Res., 38, D787-D791.
25. Zimmermann, G. R., Lehar, J. and Keith, C. T. (2007) Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today., 12, 34-42.
26. Tao, L., Zhu, F., Xu, F., Chen, Z., Jiang, Y. Y. and Chen, Y. Z. (2015) Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs. Pharmacol. Res., 102, 123-131.
27. Jia, J., Zhu, F., Ma, X., Cao, Z., Cao, Z. W., Li, Y., Li, Y. X. and Chen, Y. Z. (2009) Mechanisms of drug combinations: interaction and network perspectives. Nat. Rev. Drug Discov., 8, 111-128.
28. Kummar, S., Chen, H. X., Wright, J., Holbeck, S., Millin, M. D., Tomaszewski, J., Zweibel, J., Collins, J. and Doroshow, J. H. (2010) Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat. Rev. Drug Discov., 9, 843-856.
29. Cao, Z. W., Han, L. Y., Zheng, C. J., Ji, Z. L., Chen, X., Lin, H. H. and Chen, Y. Z. (2005) Computer prediction of drug resistance mutations in proteins. Drug Discov. Today, 10, 521-529.
30. Iskar, M., Campillos, M., Kuhn, M., Jensen, L. J., van Noort, V. and Bork, P. (2010) Drug-induced regulation of target expression. PLoS Comput. Biol., 6, e1000925.
31. Csermely, P., Agoston, V. and Pongor, S. (2005) The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol. Sci., 26, 178-182.
32. Zhu, F., Han, L., Zheng, C., Xie, B., Tammi, M. T., Yang, S., Wei, Y. and Chen, Y. (2009) What are next generation innovative therapeutic targets? clues from genetic, structural, physicochemical, and systems profiles of successful targets. J. Pharmacol. Exp. Ther., 330, 304-315.
33. Xue, W., Wang, P., Li, B., Li, Y., Xu, X., Yang, F., Yao, X., Chen, Y. Z., Xu, F. and Zhu, F. (2016) Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: an insight from molecular dynamics simulation study. Phys. Chem. Chem. Phys., 18, 3260-3271.
34. Hauschild, A., Grob, J. J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H. Jr, Kaempgen, E. et al. (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet, 380, 358-365.
35. Li, B., Tang, J., Yang, Q., Li, S., Cui, X., Li, Y., Chen, Y., Xue, W., Li, X. and Zhu, F. (2017) NOREVA: normalization and evaluation of MS-based metabolomics data. Nucleic Acids Res., 45, W162-W170.
36. Li, B., Tang, J., Yang, Q., Cui, X., Li, S., Chen, S., Cao, Q., Xue, W., Chen, N. and Zhu, F. (2016) Performance evaluation and online realization of data-driven normalization methods used in LC/MS based untargeted metabolomics analysis. Sci. Rep., 6, 38881.
37. Forbes, S. A., Beare, D., Boutselakis, H., Bamford, S., Bindal, N., Tate, J., Cole, C. G., Ward, S., Dawson, E., Ponting, L. et al. (2017) COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res., 45, D777-D783.
38. Jia, B., Raphenya, A. R., Alcock, B., Waglechner, N., Guo, P., Tsang, K. K., Lago, B. A., Dave, B. M., Pereira, S., Sharma, A. N. et al. (2017) CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database. Nucleic Acids Res., 45, D566-D573.
39. Tang, M. W., Liu, T. F. and Shafer, R. W. (2012) The HIVdb system for HIV-1 genotypic resistance interpretation. Intervirology, 55, 98-101.
40. Sandgren, A., Strong, M., Muthukrishnan, P., Weiner, B. K., Church, G. M. and Murray, M. B. (2009) Tuberculosis drug resistance mutation database. PLoS Med., 6, e2.
41. Barrett, T., Wilhite, S. E., Ledoux, P., Evangelista, C., Kim, I. F., Tomashevsky, M., Marshall, K. A., Phillippy, K. H., Sherman, P. M., Holko, M. et al. (2013) NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Res., 41, D991-D995.
42. Cancer Genome Atlas Research, N. (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 455, 1061-1068.
43. Liu, Y., Hu, B., Fu, C. and Chen, X. (2010) DCDB: drug combination database. Bioinformatics, 26, 587-588.
44. MacLean, R. C., Hall, A. R., Perron, G. G. and Buckling, A. (2010) The population genetics of antibiotic resistance: integrating molecular mechanisms and treatment contexts. Nat. Rev. Genet., 11, 405-414.
45. Bell, D. W., Gore, I., Okimoto, R. A., Godin-Heymann, N., Sordella, R., Mulloy, R., Sharma, S. V., Brannigan, B. W., Mohapatra, G., Settleman, J. et al. (2005) Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat. Genet., 37, 1315-1316.
46. UniProt, C. (2015) UniProt: a hub for protein information. Nucleic Acids Res., 43, D204-D212.
47. Lukk, M., Kapushesky, M., Nikkila, J., Parkinson, H., Goncalves, A., Huber, W., Ukkonen, E. and Brazma, A. (2010) A global map of human gene expression. Nat. Biotechnol., 28, 322-324.
48. Torrente, A., Lukk, M., Xue, V., Parkinson, H., Rung, J. and Brazma, A. (2016) Identification of cancer related genes using a comprehensive map of human gene expression. PLoS One, 11, e0157484.
49. Gautier, L., Cope, L., Bolstad, B. M. and Irizarry, R. A. (2004) affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics, 20, 307-315.
50. Bolstad, B. M., Irizarry, R. A., Astrand, M. and Speed, T. P. (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics, 19, 185-193.
51. Cheadle, C., Vawter, M. P., Freed, W. J. and Becker, K. G. (2003) Analysis of microarray data using Z score transformation. J. Mol. Diagn., 5, 73-81.
52. Dancey, J. E. and Chen, H. X. (2006) Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat. Rev. Drug Discov., 5, 649-659.
53. Coordinators, N. R. (2017) Database Resources of the National Center for Biotechnology Information. Nucleic Acids Res., 45, D12-D17.
54. Sillitoe, I., Lewis, T. E., Cuff, A., Das, S., Ashford, P., Dawson, N. L., Furnham, N., Laskowski, R. A., Lee, D., Lees, J. G. et al. (2015) CATH: comprehensive structural and functional annotations for genome sequences. Nucleic Acids Res., 43, D376-D381.
55. Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. and Tanabe, M. (2016) KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res., 44, D457-D462.
56. Altschul, S. F., Gish, W., Miller, W., Myers, E. W. and Lipman, D. J. (1990) Basic local alignment search tool. J. Mol. Biol., 215, 403-410.
57. Bienfait, B. and Ertl, P. (2013) JSME: a free molecule editor in JavaScript. J. Cheminform., 5, 24.
58. Qin, C., Zhang, C., Zhu, F., Xu, F., Chen, S. Y., Zhang, P., Li, Y. H., Yang, S. Y., Wei, Y. Q., Tao, L. et al. (2014) Therapeutic target database update 2014: a resource for targeted therapeutics. Nucleic Acids Res., 42, D1118-D1123.
59. Chen, X., Ji, Z. L. and Chen, Y. Z. (2002) TTD: therapeutic target database. Nucleic Acids Res., 30, 412-415.
60. Zhu, F., Shi, Z., Qin, C., Tao, L., Liu, X., Xu, F., Zhang, L., Song, Y., Liu, X., Zhang, J. et al. (2012) Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res., 40, D1128-D1136.
61. Weiner, G. J. (2015) Building better monoclonal antibody-based therapeutics. Nat. Rev. Cancer, 15, 361-370.
62. Rupaimoole, R. and Slack, F. J. (2017) MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov., 16, 203-222.